ArticleThe Journal of allergy and clinical immunology2014
Case fatality and population mortality associated with anaphylaxis in the United States.
Article in The Journal of allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.
- The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.The journal of allergy and clinical immunology. In practice · 2021Pooled it
- Role of Non-Thermal Processing Technologies in Modulating Protein Allergenicity in Legumes.Food science & nutrition · 2026Review
- Treatment Preferences in Acute Allergic Reactions-How Can the Context Impact the Preference for a Corticosteroid Mouth Film Versus Conventional Tablets?Journal of market access & health policy · 2026Article
- Epinephrine nasal spray for anaphylaxis: a preferred needle-free self-treatment.Annals of medicine and surgery (2012) · 2026Article
- Label-free, machine-learning assisted impedance assessment of basophil activation.Sensors and actuators. B, Chemical · 2026Article
- Acute Allergic Reactions and Severe Anaphylaxis: Underlying Causes, Management Strategies, and Future Directions.Archives of internal medicine research · 2026Article
- Neutrophil extracellular trap-associated responses are associated with tissue factor expression and coagulation abnormalities during anaphylaxis.Frontiers in immunology · 2026Article
- A critical case of anaphylaxis triggered by exercise in a pediatric asthma patient.BMC pediatrics · 2025Article
- Utility of in Vivo and Ex-vivo Models in Food Allergy Research: Lessons for Shrimp Allergy.Clinical reviews in allergy & immunology · 2025Review
- Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025Review
- Lactate in Anaphylaxis: 100 Years On.Sports medicine (Auckland, N.Z.) · 2025Review
- Identifying key risk factors for severe pediatric anaphylaxis in children aged 0 to 15: Evidence from a Thai study.Asia Pacific allergy · 2025Article
- A hand-operated microfluidic sample preparation-to-analysis workflow for simplifying the basophil activation test.Lab on a chip · 2025Article
- Component-Resolved and Multiplex-Specific IgE Diagnostics: Utility in Anaphylaxis and Beyond.Children (Basel, Switzerland) · 2025Review
- Emergency Monitoring Following A Diagnosis of Anaphylaxis.Current allergy and asthma reports · 2025Review
- Cost-effectiveness of watchful waiting versus immediate emergency department transfer after epinephrine autoinjector use in Canada.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- A new experimental model of peanut allergy in BALB/c and C57BL/6 mice.Frontiers in allergy · 2025Article
- Assessment of allergy knowledge among the Palestinian community: A cross-sectional study.PloS one · 2025Observational
- Anaphylaxis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Review
- Epidemiology, Risk Factors, and Management of Biphasic Anaphylaxis.Current allergy and asthma reports · 2024Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAnaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear.
objectiveWe sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population.
methodsThis was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively.
resultsCase fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%).
conclusionFrom 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.